223 related articles for article (PubMed ID: 29576533)
1. Dual Modifications of α-Galactosylceramide Synergize to Promote Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor Immunity.
Chennamadhavuni D; Saavedra-Avila NA; Carreño LJ; Guberman-Pfeffer MJ; Arora P; Yongqing T; Pryce R; Koay HF; Godfrey DI; Keshipeddy S; Richardson SK; Sundararaj S; Lo JH; Wen X; Gascón JA; Yuan W; Rossjohn J; Le Nours J; Porcelli SA; Howell AR
Cell Chem Biol; 2018 May; 25(5):571-584.e8. PubMed ID: 29576533
[TBL] [Abstract][Full Text] [Related]
2. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
3. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
[TBL] [Abstract][Full Text] [Related]
4. Tweaking α -Galactoceramides: Probing the Dynamical Mechanisms of Improved Recognition for Invariant Natural Killer T-cell Receptor in Cancer Immunotherapeutics.
Washah H; Agoni C; Olotu FA; Munsamy G; Soliman MES
Curr Pharm Biotechnol; 2020; 21(13):1354-1367. PubMed ID: 31738132
[TBL] [Abstract][Full Text] [Related]
5. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
[TBL] [Abstract][Full Text] [Related]
6. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
[TBL] [Abstract][Full Text] [Related]
7. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
Front Immunol; 2019; 10():352. PubMed ID: 30881361
[TBL] [Abstract][Full Text] [Related]
8. Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases.
Laurent X; Bertin B; Renault N; Farce A; Speca S; Milhomme O; Millet R; Desreumaux P; Hénon E; Chavatte P
J Med Chem; 2014 Jul; 57(13):5489-508. PubMed ID: 24428717
[TBL] [Abstract][Full Text] [Related]
9. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
[TBL] [Abstract][Full Text] [Related]
10. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
[TBL] [Abstract][Full Text] [Related]
11. Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
Lameris R; Schneiders FL; de Gruijl TD; van der Vliet HJ
Methods Mol Biol; 2014; 1139():155-65. PubMed ID: 24619678
[TBL] [Abstract][Full Text] [Related]
12. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
Front Immunol; 2019; 10():2355. PubMed ID: 31649670
[TBL] [Abstract][Full Text] [Related]
13. CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S; Perret R; Derré L; Zhang L; Stirnemann K; Zauderer M; Speiser DE; Mach JP; Romero P; Donda A
Cancer Immunol Immunother; 2013 Apr; 62(4):747-60. PubMed ID: 23242316
[TBL] [Abstract][Full Text] [Related]
14. Activation of iNKT Cells Facilitates Liver Repair After Hepatic Ischemia Reperfusion Injury Through Acceleration of Macrophage Polarization.
Goto T; Ito Y; Satoh M; Nakamoto S; Nishizawa N; Hosono K; Naitoh T; Eshima K; Iwabuchi K; Hiki N; Amano H
Front Immunol; 2021; 12():754106. PubMed ID: 34691073
[TBL] [Abstract][Full Text] [Related]
15. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
[TBL] [Abstract][Full Text] [Related]
16. Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after alpha-galactosylceramide administration.
Kuns RD; Morris ES; Macdonald KP; Markey KA; Morris HM; Raffelt NC; Banovic T; Don AL; Rowe V; Burman AC; Clouston AD; Farah C; Besra GS; Illarionov PA; Smyth MJ; Porcelli SA; Hill GR
Blood; 2009 Jun; 113(23):5999-6010. PubMed ID: 19369232
[TBL] [Abstract][Full Text] [Related]
17. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
18. Solubilization of α-galactosylceramide in aqueous medium: Impact on Natural Killer T cell activation and antitumor responses.
Macho-Fernandez E; Chekkat N; Ehret C; Thomann JS; De Giorgi M; Spanedda MV; Bourel-Bonnet L; Betbeder D; Heurtault B; Faveeuw C; Fournel S; Frisch B; Trottein F
Int J Pharm; 2017 Sep; 530(1-2):354-363. PubMed ID: 28743554
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties.
Kerzerho J; Yu ED; Barra CM; Alari-Pahissa E; Girardi E; Harrak Y; Lauzurica P; Llebaria A; Zajonc DM; Akbari O; Castaño AR
J Immunol; 2012 Mar; 188(5):2254-65. PubMed ID: 22301545
[TBL] [Abstract][Full Text] [Related]
20. Graphene oxide polarizes iNKT cells for production of TGFβ and attenuates inflammation in an iNKT cell-mediated sepsis model.
Lee SW; Park HJ; Van Kaer L; Hong S; Hong S
Sci Rep; 2018 Jul; 8(1):10081. PubMed ID: 29973666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
